Ledipasvir / Sofosbuvir
Ledibiox is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
Dosage and Administration:
The recommended dose for Ledibiox is one tablet (90 mg of ledipasvir and 400 mg of sofosbuvir) taken orally once daily with or without food.
A dose recommendation cannot be made for patients with severe renal impairment or end stage renal disease.
The most common adverse reactions with Ledipasvir/Sofosbuvir are fatigue and headache (≥10%). Nausea, diarrhea and insomnia are observed in ≥5% of patients receiving Ledipasvir/Sofosbuvir treatment. Elevations in bilirubin, lipase and creatine kinase have been reported in less than 3%.